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Abstract 
Gliomas are the most common CNS tumours in children and present either as circumscribed tumours or diffusely 
infiltrative neoplasms. Diffuse gliomas develop both in the cerebral hemispheres and the brainstem and have a 
poor prognosis. Guidelines for the therapy of these tumours are still debated. In this study, we reviewed the 
clinical features of 27 consecutive patients with diffuse gliomas admitted to the Department of Paediatrics of 
CHR Citadelle, University of Liège, between 1985 and 2005. We review their clinical presentation, diagnosis, 
treatment and outcome with reference to the published literature. 
Key words : Diffuse gliomas ; children ; clinical study ; supratentorial ; brainstem. 
 
Introduction 
Paediatric central nervous system (Hunter et al., 2002) tumours represent 20% of all childhood cancer (age 0-14 
years). Gliomas account for 42% to 66% of all paediatric CNS tumours. By decreasing frequency, they consist of 
pilocytic astrocytomas (21% and 16% of CNS tumours from 0-14 and 15-19 years, respectively), ependymomas 
(10-15% of CNS tumours) and a group of astrocytic and oligodendroglial tumours WHO grade II, III and IV that 
are usually referred together as diffuse gliomas, as they show a distinctively infiltrative pattern of growth (WHO 
classification 2007) (see Table 1). At the microscopic level the distinction between the diffuse gliomas and the 
more circumscribed ones, particularly pilocytic astrocytomas, is somewhat artificial as pilocytic astrocytomas 
can be shown to permeate the brain parenchyma over mm to centimetres (WHO classification 2007). At the 
clinical level, the treatment of pilocytic tumours may be challenging as they tend to localize in the optic 
chiasma/hypothalamus and central grey nuclei in children. However, pilocytic astrocytomas, as a whole, have a 
slow growth and a low rate of recurrence. Their management is primarily surgical and their overall prognosis is 
favourable when amenable to complete surgical resection. By contrast, diffuse gliomas show a wide range of 
growth rate, a tendency to progress towards anaplasia and recurrence is the rule. Their treatment comprises 
surgery, irradiation and chemotherapy but their prognosis remains poor, particularly for high grade and 
brainstem tumours. 
In this review, we have only included low grade and high grade diffuse gliomas as defined above. As in adults, 
diffuse gliomas can show histological features of astrocytic, oligodendroglial or mixed differentiation, but in 
children, tumours with an oligodendroid appearance are relatively rare (Razack et al., 1998). Based on their 
morphological features and proliferative rate, they are usually grouped as high-grade (WHO grade III and IV) or 
low-grade (Brada et al., 2003) tumours. By contrast with adults, where glioblastomas are the most frequent 
primary CNS tumours, high grade supratentorial gliomas are infrequent in children (Peris-Bonet et al., 2006) and 
represent 6%-12% of all primary paediatric brain tumours (Pollack, 1994). In the U.S., from 1995 to 1999, the 
overall incidence of paediatric high-grade gliomas was 0.63 per 100,000 person-year (Broniscer et al., 2004). 
Location in the brainstem is seen in 3%-9% of paediatric primary CNS tumours, a figure much higher than in 
adults (Pollack, 1994). Whether low-grade or high-grade, brainstem gliomas are particularly challenging for the 
oncologist as surgery is usually not an option. 
Because of the low incidence of diffuse childhood gliomas, few randomised studies have been reported that 
specifically address the paediatric population and the guidelines for treatment are still debated. Furthermore, the 
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patterns of genetic alterations are still poorly documented in child tumours, preventing the development of 
targeted therapies. 
Finally, long term toxicity is always a major concern when treating a child, limiting the use of drugs and 
radiation. 
In this paper, we review 27 consecutive cases of diffuse gliomas, diagnosed and treated in the Department of 
Paediatrics, Hôpital de la Citadelle (University of Liège), between 1985 and 2005. The charts were carefully 
reviewed for clinical, radiological and pathological features of the brain tumours and for patient's outcome under 
the various therapeutic regimens that were recommended at time of diagnosis. 
 
Table 1 WHO grading of gliomas 
 Histological sub-type   WHO grade Astocytic tumours Oligodendroglial tumours Oligoastrocytic tumours 
 
Grade I Pilocytic astrocytoma 
(ICD-O code 9421/1) 
- - 
Low 
grade Grade II Diffuse Astrocytoma 
(ICD-O code 9400/3) 
Oligodendroglioma  
(ICD-O code 9450/3) 
Oligoastrocytoma  
(ICD-O code 9382/3) 
Grade III Anaplastic astrocytoma 
(ICD-O code 9401/3) 
Anaplastic 
oligodendroglioma  
(ICD-O code 9451/3) 
Anaplastic 
oligo-astrocytoma 
(ICD-O code 9382/3) 
Diffuse 
Gliomas High 
grade Grade IV Glioblastoma  
(ICD-O code 9440/3) 
- - 
 
Patients and methodology 
Twenty-seven consecutive cases of paediatric diffuse glioma were diagnosed and treated in the Department of 
Paediatrics, University of Liège, Hôpital de la Citadelle, between 1985 and 2005. Paediatric group was defined 
as 0-16 years of age. Charts were carefully reviewed for patients and tumours characteristics (displayed in Tables 
2 and 3). Diagnosis was made either on histology or on the combination of clinical and radiological features. The 
percentage of cases with diagnosis based on histology was 96% (26/27). Follow up was not systematically 
organized in the hospital and was made through general neurosurgical or oncologists consultations. No child was 
lost or excluded from the follow up. Except for one patient with grade II astrocytoma who died of tumour 
progression after 20 years, death always occurred within the 2 years following diagnosis. Among survivors, the 
mean follow up was 5.8 years (1.6-10.7). All patients were treated according to the gold standard protocols 
prevailing at the time of diagnosis, including the BB SFOP protocol (carboplatin, procarbazin, etoposide, 
cisplatin, vincristin and cyclophosphamide) (Dufour et al., 2006), the HIT-GBM 89 (CCNU, vincristin and 
prednisolone), the 8-in-1  regimen (vincristine, CCNU, procarbazine, hydroxyurea, cisplatin, cytarabine, 
dacarbine, and methylprednisolone) (Finlay et al., 1995) and Temozolomide alone. 
Results 
Epidemiology 
Among the 27 followed children, 19 were female and 8 were male. The sex ratio (girl/boy) was 5/3 for grade II 
supratentorial gliomas, 4/1 for grades III supratentorial gliomas, 4/1 for grades IV supratentorial gliomas and 6/3 
for diffuse brainstem gliomas (Fig. 1). 
The mean age at diagnosis was 8.9 y (0.2-15.3). High grade glioma predominantly occurs in young patients and 
85% (12/14) of patients with grades III and IV gliomas were < 10 y. By contrast, grade II glioma tend to develop 
in older patients, since 58% (7/12) of patients with grade II glioma were over 10 y. 
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Two patients had a particular personal history suggestive a possible genetic background favouring the 
development of brain tumours. The first (case 1) had Langerhans cell histiocytosis treated by chemo- and 
radiotherapy until the age of one year and developed a temporal oligodendroglioma grade II at the age of 15 
years. The second patient (case 9) had a family history of type 1 neurofibromatosis and developed a thalamic 
astrocytoma grade III at the age of 4 y. 
Presenting symptoms 
The mean interval between onset and diagnosis was 5 months with a maximum of 30 months. This interval was 
of 4.3 months for supra-tentorial infiltrative gliomas and of 5.4 months for diffuse brainstem gliomas. 
In supratentorial tumours, the mean time before diagnosis was of 3,6 months for grade II, 6 months for grade III 
and 4 months for grade IV gliomas. 
Symptoms leading to delayed diagnosis were isolated headache (24 and 30.05 months) and behavioural changes 
(12 months). 
Conversely, diagnosis was made early for cases presenting with visual disturbance of acute onset or cranial nerve 
palsies (0.23 and 0.94 month), intracranial hypertension (1.48, 0.99, 0.33, 0 and 1.05 months), generalized 
seizures (0 and 0.13 months), limb paresia (0.46 and 1.25 months) and ear nose throat (ENT) manifestations such 
as dysphagia or dysarthria (0.99 and 0.33 month). 
Symptoms at onset were related to tumour location (Tables 4 and 5). Visual disturbance and ataxia were mostly 
seen with brainstem tumours. Headache, hemiparesia and vomiting were frequent and encountered with all 
tumour types and location. Acute raised intracranial pressure was frequently present in high grade supra-tentorial 
gliomas. Ataxia, vertigo, dysarthria, dysphagia and hemihypoesthesia were only seen in brainstem glioma. 
Finally, asthenia was only reported in high grades tumours, either supra- or infra-tentorial. 
The neurological examination at diagnosis was abnormal in a majority of patients. However, it was reported as 
normal for 7 patients, 5 with a temporal tumour, 1 with a left parietal tumour and the last with a tectal tumour. 
Treatment and outcome 
Grade II supratentorial gliomas (n = 8) 
The five-year survival was 90% (Fig. 2) and the mean follow up of survivors was 4.7 years (1.6-10). 
Complete resection was obtained in 5 cases. All patients achieved complete remission without adjuvant 
treatment (cases 1, 2, 3, 6, 7). 
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Biopsy alone was performed in 3 patients. The first patient achieved partial remission at 10 years (case 4).The 
second died after 0.3 years of evolution because of tumour progression despite radiotherapy (case 5). The third 
(case 8) had tumour recurrence 10 years after diagnosis, with progression to anaplasia (grade III astrocytoma). 
The patient died after 20.2 years of tumour progression despite radio- and chemotherapy. 
Therefore, complete resection was associated with a better prognosis, as reported in the literature (Campbell et 
al., 1996) (Wisoff et al., 1998) (Kramm et al., 2006). 
FIG. 2. — Survival rate by tumour type. 
 
 
FIG. 3. — Brainstem grade III astrocytoma of the left part of the protuberance, with partial contrast 
enhancement (patient 24). 
 
 
FIG. 4. — Tectal grade II fibrillary astrocytoma (patient 2). 
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Grade III and IV supratentorial gliomas (n = 10) 
For grade III tumours, the 5-year survival was 40% (2/5) (Fig. 2), with a follow up respectively of 8.5 and 10.7 
years for the two survivors (cases 9 and 10). The two patients who achieved prolonged complete remission were 
those who benefited from complete surgical resection. In the other cases, only an open or stereotactic biopsy 
(patients number 11 and 13) or a partial surgical excision could be performed (patient number 12) and death 
ensued within two years following diagnosis despite adjuvant radio- or chemotherapy. 
For glioblastoma, the 5-year survival was 20% (1/5) (Fig. 2), with a follow up of 5.7 years for the survivor. Only 
one patient benefited from macroscopically complete resection but he died rapidly due to tumour recurrence 
(patient 16). In the other four cases, surgery was only partial. Three patients (cases 14, 15 and 18) died within 
two years following diagnosis. A 6-year old girl with left parietal glioblastoma achieved prolonged complete 
remission with radio- and chemotherapy (patient 17). This girl presented with a 5 week history of asthenia, 
vomiting and right hemiparesis. Total resection was obtained in two steps and followed by radiotherapy (60 Gy). 
After two months, the patient developed headache, vomiting and right hemiparesis. Control MRI showed 
recurrence of a mainly cystic tumour which was drained. Temozolomide was then given for 4 years, leading to 
complete tumour regression and prolonged second complete remission (5.7 years). Unfortunately, the patient 
kept sequellae with right hemiparesis and dysarthria. 
As expected, the time interval between onset and diagnosis was of prognostic significance. Indeed, all patients 
with a delay before diagnosis > 1.5 years died, while 3/5 patients with a delay < 1.5 years are alive. For patients 
with complete remission, diagnosis was always made during the first 18 months of evolution. 
Finally, in this series, age at diagnosis was not predictive of outcome. In larger studies, younger age has been 
shown to be of better prognosis (Finlay et al, 1995 ; Wisoff et al, 1998) but these data are still debated. 
Brainstem glioma (n = 9) 
Eight patients died shortly after the onset of symptoms and the mean survival was 0.7 years (Fig. 2). All had 
received radiotherapy and 5 of them were also treated with chemotherapy (3 with temozolomide alone, 1 with 
fotemustine and 8-in-1 regimen and one with vincristine and carboplatine). One patient (case 27) with a grade II 
glioma achieved partial remission at 5 years, after biopsy and chemotherapy. This 14-years-old boy, with Chiari 
malformation, presented with a one year history of left hemifacial spasm, cerebellar signs and left inferior 
hemihypoesthesia. MRI showed an expansive lesion of the left part of brainstem, without contrast enhancement. 
Histology was made on open biopsy and showed a grade II glioma. Treatment by chemotherapy following 
Packer (vincristine, carboplatine) was given leading to prolonged partial remission. 
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Table 2 Patients Characteristics See "Diffuse gliomas Table 2" 
Case Gender Age 
(years) 













Chemotherapy Follow up (years) 
1 f 15 2002 Temporal, right Oligodendroglioma II  Convulsion Normal 0,0 Surgical 
specimen 
Complete No No Complete remission 
(4.5) 
2 m 4 2004 Tectum Fibrillary 
astrocytoma 








No No Complete remission 
(2.3) 
3 f 5 2004 Cerebellar 
vermis 
Astrocytoma II Ki67 : 1 Ophtalmic 
manifestations, 
headeache 
Strabism 6,4 Surgical 
specimen 
Complete No No Complete remission 
(2.3) 








Biopsy No No Partial remission 
(10.1) 









Biopsy Yes No Progression. 
Tumour related 
death (0.3) 
6 f 6 1999 Parietal, left Astrocytoma II  Convulsion Normal 5,4 Surgical 
specimen 
Complete No No Complete remission 
(7.5) 












No No Complete remission 
(1.6) 
8 m 1 1985 Fronto-parietal, 
left 
Astrocytoma II Ki 67 : 3 Convulsion Right hemiparesis 5,0 Open biopsy Open biopsy Yes BB SFOP (b) Progression. 
Tumour related 
death (20.2) 
                
9 f 4 1996 Thalamus, left Astrocytoma III Ki67 : 0 Right hemiparesis Right hemiparesis with 
no involvement of the 






No BB SFOP (b) Complete remission 
(8.5) 
10 f 1 1996 Fronto-
temporo-
parietal, left 
Astrocytoma III  Ophtalmic 
manifestations, 
vomiting, apathy 
Fever, bulging fontanelle, 





No BB SFOP (b) Complete remission 
(10.7) 
11 f 0 1996 Diencephalon Astrocytoma III  Anorexy Macrocephaly, bulging 
fontanelle 
2,6 Open biopsy Biopsy No No Progression. 
Tumour related 
death (0) 
12 f 15 1998 Temporal, left Astrocytoma III  Ophtalmic 
manifestations, 
headache, vomiting 
Normal 0,6 Surgical 
specimen 
Incomplete Yes Vincristine Progression. 
Tumour related 
death (0.2) 
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Lethargy, right facial 
hemiparesis bilateral 6th 
cranial nerve palsies. 
24,0 Open biopsy Biopsy No BB SFOP (b) Progression. 
Tumour related 
death (1.8) 
                
14 f 7 1994 Frontal, right Glioblastoma IV  Acute intracranial 
hypertension 
Left hemiparesis 0,0 Surgical 
specimen 






15 f 9 1998 Thalamus, right Glioblastoma IV Ki67 : 3 Acute intracranial 
hypertension 
Left babinski 1,5 Surgical 
specimen 
Incomplete Yes Temozolomide Progression. 
Tumour related 
death (1.4) 





Normal 12,1 Surgical 
specimen 
Complete No BB SFOP (b) Relapse (after 5 
months). Palliative 
treatment. Tumour 
related death (0.5) 














18 f 6 2005 Right 
hemisphere 





Left pyramidal syndrom, 
left cerebellar syndrom 
6,2 Surgical 
specimen 
Incomplete Yes Temozolomide Progression. 
Tumour related 
death (0.1) 
                




Biopsy Yes No Progression. 
Tumour related 
death (0.9) 







syndrome, central left 7th 
cranial nerve palsy. 
0,3 Stereotactic 
biopsy 
Biopsy Yes No Progression. 
Tumour related 
death (0.6) 




Cranial nerve palsies (VI)  Open biopsy Biopsy Yes Temozolomide Progression. 
Tumour related 
death (0.3) 





cranial nerve palsies (V, 




Biopsy Yes No Progression. 
Tumour related 
death (1.1) 
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23 f 14 1999 Brainstem Fibrillary 
astrocytoma 
II  Headache, 
vomiting, 
dysphagia, ataxia 






24 f 7 2004 Brainstem Astrocytoma III Ki67 : 3 
p53 :3 




Yes Temozolomide Progression. 
Tumour related 
death (1.2) 






involving the face, left 
pyramidal syndrom, 
ataxia. 
3,0 Radiologic No surgery Yes Temozolomide Progression. 
Tumour related 
death (0.5) 




Bilateral myosis, left 
hemiparesis, left inferior 
limb myoclonia. Glasgow 
9/15. 
0,1 Open biopsy Open biopsy Yes No Progression. 
Tumour related 
death (0.9) 




Left facial hemispasm, 
left 
dysmetria, hemi-hypoes- 
thesia of the left inferior 
limb. Romberg sign. 




a.  1 = low, 2 = moderate, 3 = high 
b. BB SFOP protocol : carboplatin, procarbazin, etoposide, cisplatin, vincristin and cyclophosphamide 
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Table 3 Characteristics of tumour groups 
 Diffuse astrocytoma  
(WHO grade II) 
Anaplastic 
astrocytoma 
(WHO grade III) 
Glioblastoma 




Number of patients 8 5 5 9 27 
Age, years      
Mean 8.9 5.5 6.5 9.2 7.9 
Range 1.3-14.9 0.2-15.3 4.5-9.2 3.7-15.2 0.2-15.3 
Sex      
Male 3 1 1 3 8 
Female 5 4 4 6 19 
Diagnosis delay, months      
Mean 3.6 6 4 5 5 
Range 0-5 0-24 0-12 0-30 0-30 
Surgery      
None - - - 1 1 
Open biopsy 1 2 - 4 9 
Stereotactic biopsy 2 -  4 4 
Subtotal resection - 1 4 - 5 
Total resection 5 2 1 - 8 
Chemotherapy 1 4 5 5 15 (51%) 
Radiotherapy 2 1 4 8 15 (51%) 
5-year survival 90% 40% 20% 10% 44% 
Follow up of survivors, years      
Mean 4.7 9 5.7 5.1 5.4 
Range 1.6-10 8.5-10.7 - - 1.6-10.7 
Table 4 Symptoms at onset 
 Supratentorial infiltrative gliomas Diffuse brainstem gliomas 
Headache 6 1 
Convulsion 5  
Ophtalmic manifestations 2 5 
Paresis 2  
Ataxia 1  
HTIC 1  
Anorexia 1  
ENT symptoms  3 
Table 5 Symptoms at diagnosis 
 Diffuse 
astrocytoma 
(WHO grade II) 
Anaplastic 
astrocytoma 
(WHO grade III) 
Glioblastoma 





Ophtalmic manifestations 3 3 - 6 12 
Headache 4 2 2 3 11 
Hemiparesis 1 3 2 4 10 
Acute intracranial 
hypertension 
- 3 5 1 9 
Ataxia 2 - - 6 8 
Nausea, vomiting 2 1 1 3 7 
Convulsions 3 1 1 - 5 
ENT symptoms - - - 5 5 
Asthenia - - 1 2 3 
Behavioural changes - - 1 - 1 
Photophobia 1 - 1 - 2 
Hemihypoesthesia - - - 2 2 
Anorexia - 1 - - 1 
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Discussion 
We have reviewed 27 consecutive cases of paediatric infiltrative gliomas and we have described their clinical 
presentation, treatment and outcome. Pilocytic astrocytoma, although it is the most common glioma in children, 
was not included in this review. This tumour typically occurs in the first two decades of life and affects midline 
structures, such as the cerebellum, the walls of the third ventricle and the anterior optic pathway. They are often 
well delineated and have a low proliferative rate. Unlike diffuse astrocytoma, progression to anaplasia is 
distinctly rare in these tumours. Complete surgical excision, when amenable, offers an excellent prognosis to 
patients. Therefore the diagnostic features and therapy of these tumours are relatively straightforward. On the 
contrary, the less frequent diffuse astrocytomas are much more controversial in terms of clinical features and 
therapy protocol. 
The aim of this work is to illustrate the specificities of diffuse gliomas in children and report the experience of a 
large referral paediatric department in Belgium between 1985 and 2005. The small number of patients included 
in this cohort prevents a meaningful statistical treatment of data. However, some trends are worth mentioning. 
Gender analysis shows a strong female predominance (F/M : 2.4/1) in our cohort of children. This distribution is 
particularly obvious for brainstem glioma and supra-tentorial high-grade tumours. However, these ratios may be 
biased by the small size of the cohort studied. Larger series of the literature suggest that the incidence of 
astrocytoma is the same in boys and girls under 15 years (Greenberg et al., 1985 ; Peris-Bonet et al., 2006). In 
adults, diffuse astrocytoma is slightly more common in men than women (Fleury et al., 1997 ; Guthrie et al., 
1990 ; Salcman et al., 1994). 
The age distribution of our cases of brainstem glioma is comparable with the reported peak of tumour prevalence 
between 6 and 10 y (Packer et al., 1992 ; Pierre-Kahn et al., 1993). In our group of supratentorial diffuse glioma, 
grades III and IV seem to occur in younger patients than grade II tumours. An extensive review of brain tumours 
in children under 4 years of age reports a higher rate of malignancy in the first year of age (Rickert et al., 1997). 
Data are conflicting regarding the impact of gender and age on prognosis. However, suggestions have been made 
that female gender and younger age may affect outcome favourably (Finlay et al., 1995 ; Wisoff et al., 1998). 
In this cohort, headache is the most frequent symptom of supra-tentorial high grade astrocytoma and sometimes 
the sole complaint, delaying the diagnosis. Isolated headache in a child, even with normal clinical examination, 
should always be explored and brain imaging considered. Nausea and vomiting never occurred in isolation but 
were always accompanied by headache, visual disturbance, paresis and ataxia. Any of these associations should 
also direct explorations towards an intracranial mass. Finally it is important to note that a normal neurological 
examination does not rule out the presence of an intracranial tumour, particularly with temporal and frontal 
location, as for 5 patients with temporal tumour in this study. 
Survival rates are comparable with larger series (Brada et al., 2003 ; Broniscer et al., 2004 ; Sposto et al., 1989) 
with 5-year survival depending on grade and location : 90% in grade II, 40% in grade III and 20% in grade IV 
supra-tentorial glioma. In the group of brainstem glioma, one patient with grade II glioma uncommonly survived 
for 5 years, after biopsy and chemotherapy associating vincristine and carboplatine. The other patients rapidly 
died, with a mean survival of 0.7 years, as expected from published large studies (Freeman et al., 2000 ; Packer 
et al., 1996). 
In supratentorial infiltrative gliomas, we observed that complete resection seems to be associated with a better 
prognosis. This observation is confirmed by larger studies (Campbell et al., 1996) ; (Wisoff et al., 1998) ; 
(Kramm et al., 2006). Fisher et al. (Fisher et al., 2001) showed that, once the patients with complete resection 
were excluded from the analysis, the extent of surgical resection lost its significance as a prognostic factor. In 
several series, the tumour location is an independent prognostic factor as well, and deep midline tumours show a 
much poorer survival than hemispheric ones but this obviously relates, at least partly, to the ability of conducting 
a complete surgical resection (Finlay et al., 1995). Two patients with complete remission had an 
oligodendroglioma (case 1) and a pleomorphic xanthoastrocytoma (case 7), which both show a longer evolution 
than astrocytomas (Ohgaki et al., 2005). Little information is available on the role of biological markers but it 
seems that overexpression of p53, high proliferation index, PTEN (phosphatase and tensin homology) mutation 
and overexpression of basic fibroblast growth factor protein (bFGF) are associated with a worse outcome in high 
grade gliomas (Broniscer et al., 2004). In contrast with adult tumours, deletions in chromosomes 1p and 19q are 
not associated with a survival advantage in pediatric high grade gliomas (Rutka et al., 2004). Unfortunately, 
these genetic studies were not performed in this series of cases. 
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In brainstem glioma, high morbidity and mortality rates are the rule and are independent of the extent of 
resection or histology and grade. For this reason, surgical resection or biopsy of a brainstem glioma is no longer 
advocated (Hargrave et al., 2006). Nevertheless, with development of targeted therapies, some study groups 
readdress the interest of stereotactic or open biopsies to correlate biological findings with drug activity (Hargrave 
et al., 2006). Moreover, occasional patients with atypical tumours in this region may benefit from a tissue 
diagnosis and partial resection (Rutka et al, 2004). This series illustrates the specific management of paediatric 
infiltrative gliomas. These tumours are much rarer in children that in adults, accounting for the few randomised 
studies specifically directed towards paediatric treatments. It is hoped that future studies will identify specific 
genetic patterns acting in paediatric glioma, allowing for the development of new targeted therapies in this 
population. 
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